{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:43:47Z","timestamp":1778071427570,"version":"3.51.4"},"reference-count":78,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 109\u20102314\u2010B\u2010010 \u2010014 \u2010MY3"],"award-info":[{"award-number":["MOST 109\u20102314\u2010B\u2010010 \u2010014 \u2010MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 110\u20102811\u2010B\u2010A49A\u2010016"],"award-info":[{"award-number":["MOST 110\u20102811\u2010B\u2010A49A\u2010016"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["VN109\u201004"],"award-info":[{"award-number":["VN109\u201004"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tumour necrosis factor inhibitors (TNFis) are commonly used for treating psoriatic diseases; however, the risk of infection while receiving TNFis remains uncertain. The aim of this study was to investigate the infection risk in patients with psoriatic disease receiving TNFis. A prospectively registered systematic literature search was conducted in Medline (PubMed), Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE and the <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link> databases from inception to December 31, 2021. We included double\u2010blind randomized controlled trials that compared TNFis or other biologics with placebo in adults with psoriasis or psoriatic arthritis. The primary outcomes included overall and serious infection risks, and secondary outcomes included upper respiratory infections and nasopharyngitis risks. The risk ratio of the dichotomous outcome was calculated using the Mantel\u2013Haenszel method with random effects, and heterogeneity was assessed using Cochran's Q statistic and quantified using the I\u2010squared statistic. A total of 48 studies with 15\u2009464 patients with psoriatic diseases were included. The meta\u2010analysis demonstrated a slightly increased overall infection risk (risk ratio\u2009=\u20091.09; 95% confidence interval, 1.02\u20131.15) but not serious infection risk (risk ratio\u2009=\u20090.95; 95% confidence interval, 0.61\u20131.49) among patients receiving TNFis. There were also no increased risks of upper respiratory infections (risk ratio\u2009=\u20091.10; 95% confidence interval, 0.94\u20131.28) or nasopharyngitis (risk ratio\u2009=\u20091.14; 95% confidence interval, 1.00\u20131.30). In subgroup analyses using the fixed effects model, only etanercept and certolizumab pegol were, respectively, associated with an increased risk of overall infection (RR\u2009=\u20091.14, 95% CI, 1.03\u20131.27) and upper respiratory infections (RR\u2009=\u20091.42, 95% CI, 1.02\u20131.98). In conclusion, evidence to date suggests an increased overall infection risk that is generally tolerable in patients with psoriatic diseases receiving TNFis. There are no increased risks of serious infections, upper respiratory infections or nasopharyngitis.<\/jats:p>","DOI":"10.1111\/jdv.18407","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T19:09:20Z","timestamp":1657134560000},"page":"2301-2315","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Infection risk in psoriatic patients receiving tumour necrosis factor inhibitors: a 20\u2010year systematic review and meta\u2010analysis of randomized controlled trials"],"prefix":"10.1111","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4753-4600","authenticated-orcid":false,"given":"Y.\u2010C.","family":"Wang","sequence":"first","affiliation":[{"name":"School of Medicine National Yang Ming Chiao Tung University  Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6591-5787","authenticated-orcid":false,"given":"Y.\u2010H.","family":"Lin","sequence":"additional","affiliation":[{"name":"School of Medicine National Yang Ming Chiao Tung University  Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1160-5083","authenticated-orcid":false,"given":"S.\u2010H.","family":"Ma","sequence":"additional","affiliation":[{"name":"School of Medicine National Yang Ming Chiao Tung University  Taipei Taiwan"},{"name":"Department of Dermatology Taipei Veterans General Hospital  Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.\u2010T.","family":"Chang","sequence":"additional","affiliation":[{"name":"School of Medicine National Yang Ming Chiao Tung University  Taipei Taiwan"},{"name":"Department of Dermatology Taipei Veterans General Hospital  Taipei Taiwan"},{"name":"Department of Dermatology National Yang Ming Chiao Tung University  Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.\u2010C.","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Medicine National Yang Ming Chiao Tung University  Taipei Taiwan"},{"name":"Department of Dermatology Taipei Veterans General Hospital  Taipei Taiwan"},{"name":"Department of Dermatology National Yang Ming Chiao Tung University  Taipei Taiwan"},{"name":"Institute of Clinical Medicine National Yang Ming Chiao Tung University  Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,7,20]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2007"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.4103\/2229-5178.193908"},{"key":"e_1_2_8_5_1","first-page":"12","article-title":"Psoriasis and depression: the role of inflammation","volume":"110","author":"Gonz\u00e1lez\u2010Parra S","year":"2019","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.4103\/ds.ds_55_20"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.4103\/ds.ds_19_19"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.4103\/ds.ds_42_20"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.4103\/ds.ds_51_20"},{"key":"e_1_2_8_10_1","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta\u2010analysis","volume":"1","author":"Sbidian E","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09941.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16919"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.09.734"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022516"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.08.029"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0341-6"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40579"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.080"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.042"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13746"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501646"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.384"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2009.00748.x"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.09.010"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.09.040"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08315.x"},{"key":"e_1_2_8_33_1","first-page":"1040","article-title":"Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy","volume":"34","author":"Genovese MC","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.05.027"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21306"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00494-z"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.04.012"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.04.013"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203696"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10941.x"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31279-5"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14015"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60125-8"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62113-9"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.07.034"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10418.x"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10419.x"},{"key":"e_1_2_8_49_1","first-page":"1177","article-title":"Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate\u2010to\u2010severe plaque psoriasis: a randomized controlled trial with open\u2010label extension","volume":"159","author":"Kerkhof PC","year":"2008","journal-title":"Br J Dermatol"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06688.x"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67763-X"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20335"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030409"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.12.1627"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02530-7"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40226"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24403"},{"key":"e_1_2_8_58_1","first-page":"1845","article-title":"Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double\u2010blind, placebo\u2010controlled multicenter trial","volume":"125","author":"Yang HZ","year":"2012","journal-title":"Chin Med J"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.03984.x"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2010.04.014"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.07.017"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67566-6"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20967"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.02.021"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04954-0"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14139"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.19.2275"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1240783"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150057"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221007"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14068"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2599"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12970"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1718102"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.01.037"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15003"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.10.007"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201244"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rky042"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18407","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.18407","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18407","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T16:13:28Z","timestamp":1692634408000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.18407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,20]]},"references-count":78,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1111\/jdv.18407"],"URL":"https:\/\/doi.org\/10.1111\/jdv.18407","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,20]]},"assertion":[{"value":"2022-03-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}